Loading...
Market
What market share will Livdelzi capture in the PBC treatment market by August 14, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from sources like IMS Health or EvaluatePharma
Story
FDA Approves Gilead's $4.3B Acquisition Drug Livdelzi for PBC
Aug 14, 2024, 07:23 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Gilead Sciences' drug Livdelzi (Seladelpar) for the treatment of primary biliary cholangitis (PBC), an autoimmune liver disease that primarily affects women. This approval follows Gilead's acquisition of CymaBay Therapeutics for $4.3 billion earlier this year. The treatment, which is used in combination with ursodeoxycholic acid, demonstrated significant improvements in liver disease markers and pruritus. The approval is based on data from the Phase 3 RESPONSE study and marks Gilead's first launch of an inflammatory drug.
View original story
Similar markets
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10 • 25%
10-20 • 25%
20-30 • 25%
More than 30 • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%